Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway

Podobne zapisy

• ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
  od: Engelman, Jeffrey A., i wsp.
  Wydane: (2005)
• Acquired Long QT Syndrome and Phosphoinositide 3-kinase
  od: Cohen, Ira S., i wsp.
  Wydane: (2017)
• Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells
  od: Ni, Jie, i wsp.
  Wydane: (2018)
• Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
  od: SONG, ZHENGBO, i wsp.
  Wydane: (2013)
• The phosphoinositide-3-kinase inhibitor PX-866 overcomes resistance to the EGFR inhibitor gefitinib in A-549 human non small cell lung cancer xenografts.
  od: Ihle, Nathan T., i wsp.
  Wydane: (2005)